Skip to main content
OpenTrials

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,080 public trials 582 recruiting studies
Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Completed

Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse

NCT01087008

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Hospital Universitari Germans Trias I Pujol Badalona, Spain
  • Hospital de la Santa Creu i Sant Pau Barcelona, Spain
  • Hospital del Mar Barcelona, Spain
  • Hospital Vall d'Hebrón Barcelona, Spain
View all 16 locations
View Trial Details
Completed

Treatment for Chronic Pain in Patients With Advanced Cancer

NCT00003687

Conditions
Amyloidosis, Blast Crisis, Blood Coagulation Disorders, +93 more
Locations
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Newfoundland Cancer Treatment and Research Foundation St. John's, Newfoundland and Labrador, Canada
  • Princess Margaret Hospital Toronto, Ontario, Canada
  • McGill University Montreal, Quebec, Canada
View Trial Details
Completed

Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00006890

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • St. Mary's/Duluth Clinic Health System Duluth, Minnesota, United States
  • Tom Baker Cancer Center - Calgary Calgary, Alberta, Canada
  • Lethbridge Cancer Clinic Lethbridge, Alberta, Canada
  • Burnaby Hospital Regional Cancer Centre Burnaby, British Columbia, Canada
View all 64 locations
View Trial Details
Completed

Combination Chemotherapy in Treating Patients With Multiple Myeloma

NCT00002678

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • St. Mary's/Duluth Clinic Health System Duluth, Minnesota, United States
  • Tom Baker Cancer Center - Calgary Calgary, Alberta, Canada
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • British Columbia Cancer Agency - Centre for the Southern Interior Kelowna, British Columbia, Canada
View all 37 locations
View Trial Details
Completed

Radiation Therapy in Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation

NCT00031668

Conditions
Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +30 more
Locations
  • Tom Baker Cancer Center - Calgary Calgary, Alberta, Canada
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Newfoundland Cancer Treatment and Research Foundation St. John's, Newfoundland and Labrador, Canada
  • Cancer Care Ontario-Hamilton Regional Cancer Centre Hamilton, Ontario, Canada
View Trial Details
Completed

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

NCT01023308

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Novartis Investigative Site Phoenix, Arizona, United States
  • Novartis Investigative Site Anaheim, California, United States
  • Novartis Investigative Site Concord, California, United States
  • Novartis Investigative Site Los Angeles, California, United States
View all 210 locations
View Trial Details
Completed

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

NCT02902965

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Fakultní nemocnice Brno Brno, Czechia
  • Fakultní nemocnice Hradec Králové Nový Hradec Králové, Czechia
  • Fakultní nemocnice Ostrava Ostrava-Poruba, Czechia
  • Všeobecná fakultní nemocnice v Praha Prague, Czechia
View all 33 locations
View Trial Details
Completed

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

NCT01587703

Conditions
Blood Protein Disorders, Bronchial Neoplasms, Carcinoma, +31 more
Locations
  • GSK Investigational Site Baltimore, Maryland, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Philadelphia, Pennsylvania, United States
  • GSK Investigational Site Nashville, Tennessee, United States
View all 17 locations
View Trial Details

Related conditions